One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Time to Change Direction in the Treatment of Relapsed Hodgkin Lymphoma?
Michael Crump, MD, FRCPC1
doi : 10.1200/JCO.20.02905
no. 2 (January 10, 2021) 97-99.
On the Road to Precision: Understanding the Biology Driving Genomic Assays
Kevin Kalinsky, MD, MS1; Alexandra Thomas, MD2; and David W. Cescon, MD, PhD3
doi : 10.1200/JCO.20.03040
no. 2 (January 10, 2021) 100-102.
Playing With Dynamite? A Cautious Assessment of TNT
Diana D. Shi , MD1 and Harvey J. Mamon, MD, PhD2
doi : 10.1200/JCO.20.02199
no. 2 (January 10, 2021) 103-106.
Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy
Paul J. Br?ckelmann, MD1; Horst Müller, PhD1; Teresa Guhl, MD1; Karolin Behringer, MD1; Michael Fuchs, MD1; Alden A. Moccia, MD2,3; ...
doi : 10.1200/JCO.20.00947
no. 2 (January 10, 2021) 107-115.
We evaluated disease and treatment characteristics of patients with relapse after risk-adapted first-line treatment of early-stage, favorable, classic Hodgkin lymphoma (ES-HL). We compared second-line therapy with high-dose chemotherapy and autologous stem cell transplantation (ASCT) or conventional chemotherapy (CTx).
Standardization of 18F-FDG–PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma
Elena Zamagni, MD, PhD1; Cristina Nanni, MD2; Luca Dozza, MS1; Thomas Carlier, PhD3; Clément Bailly, MD, PhD3; Paola Tacchetti, MD1; ...
doi : 10.1200/JCO.20.00386
no. 2 (January 10, 2021) 116-125.
18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is currently the standard technique to define minimal residual disease (MRD) status outside the bone marrow (BM) in patients with multiple myeloma (MM). This study aimed to define criteria for PET complete metabolic response after therapy, jointly analyzing a subgroup of newly diagnosed transplantation-eligible patients with MM enrolled in two independent European randomized phase III trials (IFM/DFCI2009 and EMN02/HO95).
Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
Richard Buus , PhD1,2; Ivana Sestak, PhD3; Ralf Kronenwett, MD, PhD4; Sean Ferree, PhD5; Catherine A. Schnabel, PhD6; Frederick L. Baehner , MD7,8; ...
doi : 10.1200/JCO.20.00853
no. 2 (January 10, 2021) 126-135.
The Oncotype DX Recurrence Score (RS), Prosigna Prediction Analysis of Microarray 50 (PAM50) Risk of Recurrence (ROR), EndoPredict (EP), and Breast Cancer Index (BCI) are used clinically for estimating risk of distant recurrence for patients receiving endocrine therapy. Discordances in estimates occur between them. We aimed to identify the molecular features that drive the tests and lead to these differences.
Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis
Daniel E. Spratt, MD1; Shawn Malone, MD2; Soumyajit Roy, MD2,3; Scott Grimes2; Libni Eapen, MD2,†; Scott C. Morgan, MD2; ...
doi : 10.1200/JCO.20.02438
no. 2 (January 10, 2021) 136-144.
There remains a lack of clarity regarding the influence of sequencing of androgen deprivation therapy (ADT) and radiotherapy (RT) on outcomes in prostate cancer (PCa). Herein, we evaluate the optimal sequencing of ADT with prostate-directed RT in localized PCa.
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors
Richard D. Baird, MD, PhD1; Constanza Linossi, MD1; Mark Middleton, MD2; Simon Lord, MD2; Adrian Harris, MD2; Jordi Rod?n, MD3,4; ...
doi : 10.1200/JCO.20.00596
no. 2 (January 10, 2021) 145-154.
A first-in-human study was performed with MP0250, a DARPin drug candidate. MP0250 specifically inhibits both vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) with the aim of disrupting the tumor microenvironment.
American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care
Nathan A. Pennell, MD, PhD1; Melissa Dillmon, MD2; Laura A. Levit, JD3; E. Allyn Moushey, MSW3; Ajjai S. Alva, MD4; Sibel Blau, MD5; ...
doi : 10.1200/JCO.20.02953
no. 2 (January 10, 2021) 155-169.
This report presents the American Society of Clinical Oncology’s (ASCO’s) evaluation of the adaptations in care delivery, research operations, and regulatory oversight made in response to the coronavirus pandemic and presents recommendations for moving forward as the pandemic recedes. ASCO organized its recommendations for clinical research around five goals to ensure lessons learned from the COVID-19 experience are used to craft a more equitable, accessible, and efficient clinical research system that protects patient safety, ensures scientific integrity, and maintains data quality. The specific goals are: (1) ensure that clinical research is accessible, affordable, and equitable; (2) design more pragmatic and efficient clinical trials; (3) minimize administrative and regulatory burdens on research sites; (4) recruit, retain, and support a well-trained clinical research workforce; and (5) promote appropriate oversight and review of clinical trial conduct and results. Similarly, ASCO also organized its recommendations regarding cancer care delivery around five goals: (1) promote and protect equitable access to high-quality cancer care; (2) support safe delivery of high-quality cancer care; (3) advance policies to ensure oncology providers have sufficient resources to provide high-quality patient care; (4) recognize and address threats to clinician, provider, and patient well-being; and (5) improve patient access to high-quality cancer care via telemedicine. ASCO will work at all levels to advance the recommendations made in this report.
Trying to Remember How We Saw Patients on That April Morning
Mikkael A. Sekeres, MD, MS1
doi : 10.1200/JCO.20.01184
no. 2 (January 10, 2021) 170-171.
Teriparatide Treatment for Medication-Related Osteonecrosis of the Jaw: Is This an Effective Option?
Yoshinari Myoken, DDS, PhD, Yoshinori Fujita, DDS, PhD, and Shigeaki Toratani, DDS, PhD
doi : 10.1200/JCO.20.02379
no. 2 (January 10, 2021) 172-173.
Reply to Y. Myoken et al
Ie-Wen Sim, MBBS(Hons), BMedSci, FRACP, Gelsomina L. Borromeo, BDSc, BSc, MScMed, PhD, FRACDS, John F. Seymour, MBBS, PhD, FRACP, and Peter R. Ebeling, MBBS, MD, FRACP
doi : 10.1200/JCO.20.02906
no. 2 (January 10, 2021) 173-174.
